Matinas BioPharma Holdings, Inc. (MTNB)
| Market Cap | 2.94M -70.9% |
| Revenue (ttm) | n/a |
| Net Income | -7.31M |
| EPS | -1.19 |
| Shares Out | 14.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 406,400 |
| Open | 0.1985 |
| Previous Close | 0.2000 |
| Day's Range | 0.1931 - 0.2000 |
| 52-Week Range | 0.1780 - 2.1400 |
| Beta | 1.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as preventi... [Read more]
Financial Performance
Financial StatementsNews
Matinas BioPharma Holdings Quarterly report: Q2 2026
Matinas BioPharma Holdings has published its Q2 2026 quarterly earnings report on August 13, 2026.
Matinas BioPharma teams with GH Power to create publicly-traded company
Matinas BioPharma (MTNB) announced that it has entered into a definitive business combination agreement with GH Power to create a NYSE-listed and publicly-traded critical minerals and clean energy com...
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization
Matinas BioPharma receives noncompliance notification from NYSE
Matinas BioPharma (MTNB) announced that it received a notice from the NYSE stating that the company is not in compliance with the NYSE American continued listing standards set forth in…
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) fr...
Matinas BioPharma files $150M mixed securities shelf
16:09 EDT Matinas BioPharma (MTNB) files $150M mixed securities shelf
Matinas BioPharma Holdings Registration statement: Registration filing
Matinas BioPharma Holdings filed a registration statement on June 16, 2026, providing details about a securities offering with the SEC.
Matinas BioPharma Holdings Quarterly report: Q1 2026
Matinas BioPharma Holdings has published its Q1 2026 quarterly earnings report on May 8, 2026.
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”) f...
Matinas BioPharma Holdings Annual report: Q4 2025
Matinas BioPharma Holdings has published its Q4 2025 annual report on March 31, 2026.
Matinas BioPharma Holdings Quarterly report: Q3 2025
Matinas BioPharma Holdings has published its Q3 2025 quarterly earnings report on November 10, 2025.
Matinas BioPharma Holdings Quarterly report: Q2 2025
Matinas BioPharma Holdings has published its Q2 2025 quarterly earnings report on August 14, 2025.
Matinas BioPharma Holdings Quarterly report: Q1 2025
Matinas BioPharma Holdings has published its Q1 2025 quarterly earnings report on May 14, 2025.
Matinas BioPharma Holdings Proxy statement: Proxy Filing
Matinas BioPharma Holdings filed a proxy statement on May 12, 2025, providing details for shareholder voting and corporate governance matters.
Matinas BioPharma Holdings Proxy statement: Proxy Filing
Matinas BioPharma Holdings filed a proxy statement on May 2, 2025, providing details for shareholder voting and corporate governance matters.
Matinas BioPharma files to sell 16.9M shares of common stock for holders
17:32 EDT Matinas BioPharma (MTNB) files to sell 16.9M shares of common stock for holders
Matinas BioPharma Holdings Registration statement: Registration Filing
Matinas BioPharma Holdings filed a registration statement on April 22, 2025, providing details about a securities offering with the SEC.
Matinas BioPharma Holdings Annual report: Q4 2024
Matinas BioPharma Holdings has published its Q4 2024 annual report on April 14, 2025.
Matinas BioPharma appoints Murphy, Neugeboren to board of directors
Matinas BioPharma (MTNB) announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025. In additi...
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugebo...
Matinas BioPharma Holdings Proxy statement: Proxy Filing
Matinas BioPharma Holdings filed a proxy statement on March 3, 2025, providing details for shareholder voting and corporate governance matters.
Matinas BioPharma Holdings Proxy statement: Proxy Filing
Matinas BioPharma Holdings filed a proxy statement on February 21, 2025, providing details for shareholder voting and corporate governance matters.
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase agreement...
Matinas BioPharma appoints Evelyn D’An to board of directors
Matinas BioPharma (MTNB) announced the appointment of Evelyn D’An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. D’An…
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair
BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent di...